Evidence map›Paper›PMID 40625770›Full record

ArticleInternational cancer conference journal2025

Definitive chemoradiotherapy for pulmonary epithelial-myoepithelial carcinoma.

Keijiro Yamauchi, Masashi Yokoyama, Kayo Ueda, Riiko Komuta, Hidetaka Tanabe, So Takata, Takafumi Yanase, Yuki Hosono, Shingo Satoh, Naoko Morishita and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International cancer conference journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Epithelial-myoepithelial carcinoma of the lung: a case report and literature review.Journal of cancer research and clinical oncology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Keijiro YamauchiDepartment of Thoracic Oncology, Osaka Habikino Medical Center, 3-7-1 Habikino, Habikino City, Osaka 583-8588 Japan.ORCID 0009-0005-2875-9320
Masashi YokoyamaDepartment of Thoracic Oncology, Osaka Habikino Medical Center, 3-7-1 Habikino, Habikino City, Osaka 583-8588 Japan.
Kayo UedaDepartment of Pathology, Osaka Habikino Medical Center, Osaka, Japan.
Riiko KomutaDepartment of Thoracic Oncology, Osaka Habikino Medical Center, 3-7-1 Habikino, Habikino City, Osaka 583-8588 Japan.
Hidetaka TanabeDepartment of Thoracic Oncology, Osaka Habikino Medical Center, 3-7-1 Habikino, Habikino City, Osaka 583-8588 Japan.
So TakataDepartment of Thoracic Oncology, Osaka Habikino Medical Center, 3-7-1 Habikino, Habikino City, Osaka 583-8588 Japan.
Takafumi YanaseDepartment of Thoracic Oncology, Osaka Habikino Medical Center, 3-7-1 Habikino, Habikino City, Osaka 583-8588 Japan.
Yuki HosonoDepartment of Thoracic Oncology, Osaka Habikino Medical Center, 3-7-1 Habikino, Habikino City, Osaka 583-8588 Japan.
Shingo SatohDepartment of Thoracic Oncology, Osaka Habikino Medical Center, 3-7-1 Habikino, Habikino City, Osaka 583-8588 Japan.
Naoko MorishitaDepartment of Thoracic Oncology, Osaka Habikino Medical Center, 3-7-1 Habikino, Habikino City, Osaka 583-8588 Japan.
Hideo MoriDepartment of Pathology, Osaka Habikino Medical Center, Osaka, Japan.
Hidekazu SuzukiDepartment of Thoracic Oncology, Osaka Habikino Medical Center, 3-7-1 Habikino, Habikino City, Osaka 583-8588 Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary epithelial-myoepithelial carcinoma (P-EMC) is a rare subtype of salivary gland tumor that is generally considered a low-grade malignancy and is treated with surgical resection. Here, we report a case of P-EMC treated with definitive chemoradiotherapy. A 68-year-old man developed P-EMC with high-grade features, a Ki-67 labeling index of 60%, and rapidly progressing disease. The patient received concurrent chemoradiotherapy with carboplatin and paclitaxel, which resulted in a significant tumor size reduction. The patient is currently alive 9 months after completing chemoradiotherapy without disease recurrence. This case suggests that platinum-based chemoradiotherapy is a viable therapeutic option for locally advanced, unresectable P-EMCs.

Indexed as

ChemoradiotherapyEpithelial-myoepithelial carcinomaLung cancerPulmonary epithelial-myoepithelial carcinomaSalivary gland tumor

Identifiers

PMID40625770
PMCPMC12229430

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.